Kelsy Ketchum

2 weeks ago | 360dx.com | Kelsy Ketchum

NEW YORK – Cancer diagnostic firm AOA Dx recently presented new data on its ovarian cancer test that shows its potential promise for detecting the disease at earlier stages. According to CEO Oriana Papin-Zoghbi, the multiomic assay, Akrivis, investigates lipids and proteins and relies on liquid chromatography-mass spectrometry, standard immunoassay, and machine learning to differentiate between ovarian cancer and other diseases.

3 weeks ago | 360dx.com | Kelsy Ketchum

NEW YORK – Researchers at the UK's University of Birmingham are using £230,000 ($305,650) in funding from Cancer Research UK's Cancer Research Horizons to further develop the lateral flow-based monitoring assay they've created for a condition that may indicate a patient is at risk of developing multiple myeloma.

4 weeks ago | 360dx.com | Kelsy Ketchum

NEW YORK – Although it had multiple products with regulatory clearance and technology that had been validated by outside users, Accelerate Diagnostics' inability to attract buyers for its instruments doomed the company. On Thursday the Tucson, Arizona-based developer of antibiotic susceptibility testing platforms and assay filed for Chapter 11 bankruptcy protection in the US Bankruptcy Court for the District of Delaware.

1 month ago | 360dx.com | Kelsy Ketchum

Note: This story has been updated with comments from the conference call to discuss the firm's financial results. NEW YORK – Despite macroeconomic uncertainty related to tariffs announced by President Donald Trump last month, Bio-Techne executives said the company is well positioned to mitigate the impact of tariffs by the end of fiscal 2025.

1 month ago | genomeweb.com | Kelsy Ketchum

Note: This story has been updated with comments from the conference call to discuss the firm's financial results. NEW YORK – Despite macroeconomic uncertainty related to tariffs announced by President Trump last month, Bio-Techne executives said the company is well positioned to mitigate the impact of tariffs by the end of fiscal 2025.